Back to Cell Types

Panc 08.13Homo sapiens (Human)Cancer cell line

Also known as: PL-9, PL9, Pa14C, Panc0813, PANC0813, PANC813, Panc813, PANC 813, Panc-813, Panc-8_13, Panc8.13, Panc08.13, Panc_08_13, PANC-08-13, Panc-08.13, Panc 8.13

🤖 AI SummaryBased on 11 publications

Quick Overview

Pancreatic cancer cell line with known chromosomal abnormalities and genetic mutations.

Detailed Summary

Panc 08.13 is a human pancreatic cancer cell line derived from a pancreatic tumor. It is characterized by multiple chromosomal abnormalities, including gains and losses of specific chromosomal regions, which are common in pancreatic cancer. The cell line has been used in studies to investigate the molecular mechanisms underlying pancreatic cancer progression and drug resistance. Research on this cell line has contributed to understanding the genetic alterations associated with pancreatic cancer, including the identification of key mutations and chromosomal changes that may influence tumor behavior and therapeutic responses. The cell line is part of a panel of cancer cell lines used for genomic and functional studies, providing insights into the heterogeneity of pancreatic cancer.

Research Applications

Genomic analysis of chromosomal abnormalities in pancreatic cancerInvestigation of genetic mutations associated with pancreatic cancer progressionStudy of drug resistance mechanisms in pancreatic cancerFunctional studies of molecular pathways in pancreatic cancer

Key Characteristics

Multiple chromosomal gains and lossesKnown genetic mutations linked to pancreatic cancerUsed in studies of tumor heterogeneity and progressionPart of a panel for genomic and functional research

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1638
Species	Homo sapiens (Human)
Tissue Source	Pancreas[UBERON:UBERON_0001264]

Donor Information

Age	85
Age Category	Adult
Sex	Male
Race	caucasian

Disease Information

Disease	Pancreatic ductal adenocarcinoma
Lineage	Pancreas
Subtype	Pancreatic Adenocarcinoma
OncoTree Code	PAAD

DepMap Information

Source Type	ATCC
Source ID	ACH-000417_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	SMAD4	p.Cys123Metfs*2 (c.366dupA) (c.366_367insA)	Homozygous	-	Unknown
MutationSimple	KRAS	p.Gly12Asp (c.35G>A)	Unspecified	-	PubMed=29786757

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

11

D13S317

13

D16S539

13

D18S51

19

D19S433

13

D21S11

32.2

D2S1338

17,18

D3S1358

16

D5S818

13,14

D7S820

11

D8S1179

10,14

FGA

21,23

Penta D

10

Penta E

5,16,17

TH01

6,9.3

TPOX

8,12

vWA

18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling.

Biankin A.V., Wu J.-M., Daly R.J.

Mol. Cell. Proteomics 15:2671-2685(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.

Linnartz R., Zubel A., Slamon D.J., Finn R.S.

Br. J. Cancer 111:1788-1801(2014).

Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity.

Iacobuzio-Donahue C.A., Eshleman J.R.

Clin. Cancer Res. 18:6519-6530(2012).

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Rottapel R., Neel B.G., Moffat J.

Cancer Discov. 2:172-189(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Molecular cytogenetic characterization of pancreas cancer cell lines reveals high complexity chromosomal alterations.

Ried T., Schrock E., Perlman E.J., Jaffee E.M.

Cytogenet. Genome Res. 118:148-156(2007).

Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays.

Kern S.E.

Cancer Res. 66:7920-7928(2006).

Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.

Kern S.E., Goggins M.G., Hruban R.H.

Cancer Res. 63:8614-8622(2003).

Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials.

Thomas M., Greten T.F., Hruban R.H., Yeo C.J., Griffin C.A.

Cancer J. Sci. Am. 4:194-203(1998).

Web Resources

dpsc.ccbr.utoronto.ca